Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-25-137803
Filing Date
2025-06-09
Accepted
2025-06-09 16:03:39
Documents
17
Period of Report
2025-06-09

Document Format Files

Seq Description Document Type Size
1 6-K d77858d6k.htm 6-K 10253
2 EX-99.1 d77858dex991.htm EX-99.1 24715
3 GRAPHIC g77858dsp001.jpg GRAPHIC 186271
4 GRAPHIC g77858dsp002.jpg GRAPHIC 216694
5 GRAPHIC g77858dsp003.jpg GRAPHIC 150675
6 GRAPHIC g77858dsp004.jpg GRAPHIC 179608
7 GRAPHIC g77858dsp005.jpg GRAPHIC 133856
8 GRAPHIC g77858dsp006.jpg GRAPHIC 96114
9 GRAPHIC g77858dsp007.jpg GRAPHIC 126324
10 GRAPHIC g77858dsp008.jpg GRAPHIC 111205
11 GRAPHIC g77858dsp009.jpg GRAPHIC 92790
12 GRAPHIC g77858dsp010.jpg GRAPHIC 111049
13 GRAPHIC g77858dsp011.jpg GRAPHIC 111604
14 GRAPHIC g77858dsp012.jpg GRAPHIC 156389
15 GRAPHIC g77858dsp013.jpg GRAPHIC 105537
16 GRAPHIC g77858dsp014.jpg GRAPHIC 112621
17 GRAPHIC g77858dsp015.jpg GRAPHIC 31695
  Complete submission text file 0001193125-25-137803.txt   2682128
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36815 | Film No.: 251033973
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)